BCL6 Promotes Glioma and Serves as a Therapeutic Target. (Proc Natl Acad Sci USA, Apr 2017)

Glioblastoma is the most aggressive cancer in the brain that currently has no adequate treatment. There could be a possibility now! The team led by Prof H. Phillip Koeffler revealed that BCL6 is a prognostic marker and a targetable glioblastoma-promoting factor.

Preleukemia: One name, many meanings. (Leukemia, Mar 2017)

Prof H. Phillip Koeffler and Ms Geraldine Leong have imparted a fascinating report on how the term ‘preleukemia’ has not only transformed through many years but also changed our approach and understanding towards managing it.

Belinostat Exerts Anti-tumor Cytotoxicity Through the Ubiquitin-proteasome Pathway in Lung Squamous Cell Carcinoma. (Mol Oncol, Apr 2017)

Due to the lack of actionable driver oncogenes, small molecule inhibitors have mostly been futile in lung SCC. Prof Goh Boon Cher and team have discovered an innovative mechanism of belinostat sensitivity against the disease. This mechanism will prove to be highly useful for further development in this research area.

A Heartwarming Gift to CSI

CSI Singapore recently received a generous gift from Miss Lee Ying. The gift will go towards supporting the non-small cell lung cancer research by Dr Azhar Ali, Senior Research Scientist.

IN THE SPOTLIGHT

ISSUE 39 | APR 2017

IN THIS ISSUE

BCL6 promotes glioma and serves as a therapeutic target

Preleukemia: One name, many meanings

Advancements in personalized therapy in lung squamous cell carcinoma

UPCOMING EVENTS

CSI Seminar
Jose Cancelas
2 May 2017

CSI Research Meeting
5 May 2017

CSI Research Meeting
19 May 2017

GRADUATE PROGRAM

Congratulations to CSI PhD Student Tham Cheng Yong!

A poster abstract submitted by CSI PhD student Tham Cheng Yong from Dr Touati Benoukraf’s group was recently selected for presentation at the Great Lakes Bioinformatics Conference. This will be held from 15 to 17 May at University of Illinois at Chicago, USA. Congratulations to Cheng Yong!